KIG
TXMD icon

Kowal Investment Group’s TherapeuticsMD TXMD Stock Holding History

Kowal Investment Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,987
Closed -$38K – 148
2022
Q1 		$38K Sell
1,987
-52
-3% -$818 0.01% 126
2021
Q4 		$37K Buy
2,039
+66
+3% +$1.98K 0.01% 114
2021
Q3 		$73K Buy
1,973
+80
+4% +$3.55K 0.02% 197
2021
Q2 		$113K Buy
1,893
+295
+18% +$17.9K 0.04% 102
2021
Q1 		$107K Buy
1,598
+143
+10% +$11.2K 0.04% 96
2020
Q4 		$100K Buy
+1,455
New +$99.3K 0.05% 90

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Kowal Investment Group's TXMD Position: Q2 2022 in Review

Kowal Investment Group sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 1,987 shares — an estimated $38K sold.

Kowal Investment Group first reported a position in TXMD in Q4 2020 and held it in 6 quarters. The position peaked at $113K in Q2 2021. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Kowal Investment Group reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Kowal Investment Group sold 1,987 TherapeuticsMD shares in Q2 2022, an estimated $38K.
  • Kowal Investment Group first reported a position in TherapeuticsMD in Q4 2020 and held it in 6 quarters.
  • Kowal Investment Group's TherapeuticsMD position peaked at $113K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Kowal Investment Group's 13F filing for Q2 2022, filed 15 Aug 2022.